OBJECTIVE: To assess the ability of multiparametric prostate magnetic resonance imaging (mpMRI) to detect prostate cancer in patients with prior negative transrectal prostate biopsy (TPB).
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
MATERIAL AND METHODS: mpMRI (TSE-T2-w, DWI and DCE sequences) was performed on 1.5T (Magnetom Avanto; Siemens Healthcare Solutions) in 150 patients suspicious of prostate cancer and with negative TPB. European Society of Urogenital Radiology (ESUR) criteria were used (score 1: clinically significant disease is highly unlikely to be present; score 2: clinically significant cancer is unlikely to be present; score 3: clinically significant cancer is equivocal; score 4: clinically significant cancer is likely to be present; score 5: clinically significant cancer is highly likely to be present). PSA measurement (total and free), digital rectal examination (DRE), transrectal ultrasound (TRU) and a second TPB (at least 14 cylinders) were performed in all patients. Variables were submitted for independent blind analysis. The accuracy of each test was measured. Stepwise selection model for prediction of prostate cancer in second TPB was developed.
RESULTS: Mean age was 66.2± 5 years (51-77), mean PSA 11.3± 9.6ng/mL (0.9-75) and mean prostatic volume 82.2±42 (20-250) cc. DRE was suspicious in 11 (7.3%) patients. The mean number of cylinders per patient sampled in second TRB was 17.6±2.7(14-22). Second TRB was positive in 28 patients (18.7%). mpMRI was positive (score 3-5) in 102 (68%), test sensibility was 92.9% and the NPV was 95.8%. The risk of prostate cancer diagnosis in second TPB is modified by: PSA velocity > 0.75 (OR 1.04 (0.99-1.08]); P=0.06), free/total ratio PSA < 15% (OR 0.37 (0.13-1.05); P=0.06), each cc. of prostate volume (OR 0.98 (0.97-1); P=0.017) and mpMRI 3-5 (OR 7.87 (1.78-34.7); P=0.006). Multivariate analysis reveals that mpMRI (OR 7.41 (1.65-33.28); P=0.009) and prostatic volume (OR 0.31 (0.12-0.78); P=0.01) are independent risk predictors of prostate cancer.
CONCLUSIONS: According to ESUR guidelines and in patients with prior negative prostate biopsy, mpMRI is a valuable tool for the prediction of prostate cancer in second TPB. Lower prostate volume, the higher reliability.
Lista F, Castillo E, Gimbernat H, Rodríguez-Barbero JM, Panizo J, Angulo JC. Are you the author?
Servicio de Urología, Hospital Universitario de Getafe, Getafe; Departamento Clínico, Facultad de Ciencias Biomédicas, Universidad Europea de Madrid, Laureate International Universities, España; Servicio de Radiodiagnóstico, Hospital Universitario de Getafe, Getafe; Departamento Clínico, Facultad de Ciencias Biomédicas, Universidad Europea de Madrid, España; Servicio de Anatomía Patológica, Hospital Universitario de Getafe, Getafe, Madrid, España.
Reference: Actas Urol Esp. 2014 Sep 26. pii: S0210-4806(14)00306-4.
Article in English, Spanish.